Manufacturing, Parenterals and Injectables

Optima will also display the freeze dryer CS and the sterility test isolator STISO at the show.

Pharmaceutical machine concepts for large and small factories of the future need to be readily available, flexible when it comes to processing variation, and modular in design.

Vetter's FOYA award-winning facility is an example of a flexible pharmaceutical and biopharmaceutical modular facility design that allows expansion of space without affecting existing operations.

Innovations in fill/finish equipment and in solid-dosage moisture-control packaging technologies were on display at INTERPHEX 2018.

Choosing the right contamination control platform requires considerable research into what a product needs for an effective process design.

Ready-to-use components eliminate the need for component preparation by the drug product manufacturer, enabling them to streamline their processes and focus on their core competencies, such as drug product development and manufacturing.

Recent technological advances help streamline the fill/finish manufacturing process.

Telstar has a dedicated process analytical technology (PAT) corner at its booth to display new developments for pharmaceutical freeze drying systems and aseptic manufacturing processes.

The companies will partner to develop smart connected monitoring and support solutions for injectable drugs.

Determining the right process conditions for a freeze-drying cycle requires an understanding of the effect of each step on the drug product.

Updated guidelines and new technologies aid visual inspection of parenteral products and packaging.

Airflow visualization studies, or smoke studies, confirm unidirectional airflow patterns in an aseptic processing facility.

Grand River Aseptic Manufacturing announces equipment purchase to add vial filling capacity.

INTERPHEX presents advances in pharmaceutical container filling, robotic handling, and serialization.

The company is launching a new pre-fabricated, ready-to-run manufacturing facility that is expected to significantly decrease the production timeline for viral vector-based therapeutics.

The company will build a high-volume manufacturing facility for their glass packaging product in Durham County, NC.

The new facility, to be built in Toronto, Canada, will significantly increase capacity for pediatric and booster vaccines.

New filling and inspection machines and new containers and closures for injectable drugs will be on display at INTERPHEX 2018.

The companies have created Syna Therapeutics, a joint venture that will develop biosimilars and new molecules.

The active pharmaceutical ingredient and excipient provider has expanded its parenteral ingredient manufacturing capacity and lab services.

Revisions to chapters on glass containers and elastomeric closures were canceled following review of comments.

Under this agreement, the companies will develop in parallel an antibody drug candidate and cell lines for other potential candidates.

Grand River Aseptic Manufacturing announces first planned investment in capacity expansion.

Materials used in the seals of split butterfly valves for aseptic pharmaceutical manufacturing should be chosen carefully.

The company is voluntarily recalling three lots of Labetalol Hydrochloride Injection, USP, 100 mg/20 mL Vial and one lot of Labetalol Hydrochloride Injection, USP, Novaplus because of the potential of cracked glass at the rim of the vials.